Rosuvastatin, Atorvastatin Have Comparable Efficacy for CAD
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 19, 2023 -- Rosuvastatin and atorvastatin have comparable efficacy for a composite outcome in adults with coronary artery disease, according to a study published online Oct. 18 in The BMJ.
Yong-Joon Lee, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues compared the long-term efficacy and safety of rosuvastatin with atorvastatin in 4,400 adults with coronary artery disease in a randomized trial conducted at 12 hospitals in South Korea. Participants were assigned to rosuvastatin or atorvastatin (2,204 and 2,196, respectively); 4,341 participants completed the trial.
The mean daily dose of study drugs was 17.1 and 36.0 mg in the rosuvastatin and atorvastatin groups, respectively, at three years. The researchers found that the primary outcome (three-year composite of all-cause death, myocardial infarction, stroke, or any coronary revascularization) occurred in 8.7 and 8.2 percent of patients in the rosuvastatin and atorvastatin groups, respectively, which was not significantly different. The mean low-density lipoprotein cholesterol level during treatment was 1.8 and 1.9 mmol/L in the rosuvastatin and atorvastatin groups, respectively. The incidence of new-onset diabetes mellitus requiring initiation of antidiabetics and cataract surgery was significantly increased in the rosuvastatin group (hazard ratios, 1.39 and 1.66, respectively). There was no between-group difference noted in other safety end points.
"Rosuvastatin and atorvastatin treatment showed comparable efficacy in terms of the composite of all cause death, myocardial infarction, stroke, or any coronary revascularization within three years," the authors write.
One author disclosed ties to pharmaceutical and medical device companies, including Sam Jin Pharmaceutical and Chong Kun Dang Pharmaceutical, which partially funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Social Determinants of Health Tied to Atherosclerotic CVD Risk
WEDNESDAY, May 1, 2024 -- Both individual- and area-level social determinants of health (SDOH) are associated with atherosclerotic cardiovascular disease (ASCVD) risk, according...
Coronary Artery Vessel Wall Thickness Increased for People Living With HIV
TUESDAY, April 16, 2024 -- Asymptomatic people living with HIV (PLWH) with a low risk for cardiovascular disease have increased coronary artery vessel wall thickness (VWT)...
Silent Brain Infarct, Cerebral Small Vessel Disease Prevalent in Heart Disease
MONDAY, April 15, 2024 -- The prevalence of silent brain infarction (SBI) and cerebral small vessel disease (CSVD) is high among individuals with heart disease and is similar with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.